910 POSTER Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinumresistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct)

首页> 外文期刊>European Journal of Cancer Supplements >910 POSTER Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinumresistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct)

【24h】

910 POSTER Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinumresistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct)

机译：910 POSTER吉西他滨（GEM）与聚乙二醇脂质体阿霉素（PLDOX）的二线或三线化疗（ct）的铂耐药性（pt-r）卵巢癌（oc）患者（pts）的III期随机试验

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
入库时间 2022-08-18 18:36:56

相似文献

外文文献
中文文献
专利

1. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. [J] . Mutch DG, Orlando M, Goss T, Journal of Clinical Oncology . 2007,第19期

机译：吉西他滨与聚乙二醇脂质体多柔比星在铂耐药性卵巢癌患者中进行的III期随机试验。
2. Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. [J] . Ferrandina G, Ludovisi M, Corrado G, Gynecologic Oncology: An International Journal . 2008,第2期

机译：Ca125反应标准和RECIST标准的预后作用：吉西他滨与聚乙二醇化脂质体阿霉素在复发性卵巢癌中的MITO-3 III期临床试验结果分析。
3. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. [J] . Pignata S, Scambia G, Ferrandina G, Journal of Clinical Oncology . 2011,第27期

机译：卡铂加紫杉醇与卡铂加聚乙二醇化脂质体阿霉素作为卵巢癌患者的一线治疗药物：MITO-2随机III期试验。
4. COMPLEMENT ACTIVATION BY PEGYLATED LIPOSOMAL DOXORUBICIN (DOXIL~R) IN CANCER PATIENTS: ASSOCIATION WITH HYPERSENSITIVITY REACTIONS [C] . A. Chanan-Khan, J. Szebeni, L. Leibes, International symposium on controlled release of bioactive materials;Consumer diversified products conference . 2001

机译：聚脂脂质体阿霉素（DOXIL〜R）在癌症患者中的补体激活：与超敏反应的关联
5. Hypotensive resuscitation versus standard fluid resuscitation for the management of trauma patients in hemorrhagic shock: The safety phase of a randomized controlled trial. [D] . Morrison, C. Anne. 2009

机译：低血压复苏与标准液体复苏在失血性休克中对创伤患者的处理：一项随机对照试验的安全性阶段。
6. Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer [O] . Bradley J. Monk, Thomas J. Herzog, George Wang, 2020

机译：先前在复发性卵巢癌中使用聚乙二醇化脂质体阿霉素（PLD）治疗的数据：来自3期随机开放标签研究的事后数据分析比较了复发性卵巢癌患者中的Trabectedin和PLD与单独使用PLD
7. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial [O] . Poveda, A., Vergote, I., Tjulandin, S., 2010

机译：曲贝汀加聚乙二醇化阿霉素在复发性卵巢癌中的治疗：OVA-301 III期随机试验的部分铂敏感（无铂间隔6-12个月）亚群的结果

910 POSTER Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinumresistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct)

著录项

相似文献

相关主题

期刊订阅